Tag: MindMed - Page 5 - Psychedelic Alpha

Read more about the article MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System

MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System

Post published:May 24, 2021
Post category:Press Release

Read more about the article MindMed Announces the Approval of Mescaline Study

MindMed Announces the Approval of Mescaline Study

Post published:May 20, 2021
Post category:Press Release

Read more about the article The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

Post published:May 18, 2021
Post category:Press Release

Read more about the article MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial

Post published:May 17, 2021
Post category:Press Release

Read more about the article MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline

MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline

Post published:May 14, 2021
Post category:Press Release

Read more about the article MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director

MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director

Post published:May 14, 2021
Post category:Press Release

Read more about the article MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

Post published:May 13, 2021
Post category:Press Release

Read more about the article MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics

MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics

Post published:May 5, 2021
Post category:Press Release

Read more about the article MindMed Begins Trading on Nasdaq

MindMed Begins Trading on Nasdaq

Post published:April 27, 2021
Post category:Press Release

Read more about the article MindMed Becomes Second Psychedelic Drug Development Company to List on the Nasdaq

MindMed Becomes Second Psychedelic Drug Development Company to List on the Nasdaq

Post published:April 27, 2021
Post category:News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.